| LBCTR2021074831 | GBT2104-132 (C5361002) | A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | GBT2104-132: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | Interventional | Other | 24/06/2021 |
| LBCTR2023115324 | P3-IMU-838-RMS-01 (ENSURE-1) | A Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 (vidofludimus calcium) versus Placebo in Adults with Relapsing Multiple Sclerosis (RMS) | A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1) | Interventional | Pending | 30/03/2023 |
| LBCTR2023075332 | ACE-536-MF-002 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE) | A phase 3, double-blind, randomized study to compare the efficacy and safety of Luspatercept (ACE-536) versus placebo in subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on concomitant JAK2 inhibitor therapy and who require red blood cell transfusions | Interventional | Recruiting | 13/04/2023 |
| LBCTR2020113522 | MERS-201 | Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers | Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers | Interventional | Complete | 28/06/2020 |
| LBCTR2020094573 | CQGE031C2302E1 | CQGE031C2302E1 Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab | A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 | Interventional | Complete | 01/09/2020 |
| LBCTR2019020191 | CAIN457M2302 | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | Interventional | Complete | 08/02/2019 |
| LBCTR2023065390 | FM446 | Effects of a mindfulness program on the welfare of university students | The effects of a mindfulness program on the reduction of symptoms of anxiety and depression and on the perception of pain and stress in university students | Interventional | Recruiting | 21/06/2023 |
| LBCTR2023065392 | CEHDF2110 | Comparison of the impact of two NEurofeedback EEG protocols on the perception and threshold of experimental pain in healthy subjects | Physiological and validation study in healthy subjects of the effect of two Neurofeedback protocols on acute pain - clinical trial. | Interventional | Recruiting | 29/06/2023 |
| LBCTR2022054889 | CBYL719G12301 | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | Interventional | Suspended | 04/11/2021 |
| LBCTR2023015151 | CLOU064C12301 | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | Interventional | Pending | 14/10/2022 |